Study of an Experimental New Drug, PPARĪ³ Agonist Taken by Mouth by Participants With Advanced or Metastatic Cancer
Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
An open-label, Phase I, dose escalation study of CS-7017 administered by mouth in sequential
cohorts of 3 to 6 participants with advanced or metastatic malignancies.